Did you know?

NL0015000DX5. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. Show more.Stock Price Forecast. The 6 analysts offering 12-month price forecasts for ATAI Life Sciences NV have a median target of 11.00, with a high estimate of 21.00 and a low estimate of 5.10.Oct 24, 2023 · That said, analysts are starting to come around on ATAI. H.C. Wainwright biotech analyst Patrick Trucchio maintained a "buy" rating on Atai in early October, with a price target of $20. Its ... A high-level overview of Atai Life Sciences N.V. (ATAI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Dec 1, 2023 · The ATA Inc. stock price gained 7.69% on the last trading day (Friday, 1st Dec 2023), rising from $1.04 to $1.12. During the last trading day the stock fluctuated 12.20% from a day low at $1.03 to a day high of $1.15. The price has risen in 5 of the last 10 days and is up by 0.9% over the past 2 weeks. Volume fell on the last day by -2 million ... Dec 15, 2022 · What's Happening With ATAI Life Sciences NV Stock Today? ATAI Life Sciences NV (ATAI) stock is trading at $3.05 as of 3:20 PM on Thursday, Dec 15, a drop of -$0.05, or -1.77% from the previous closing price of $3.10. The stock has traded between $2.98 and $3.10 so far today. Volume today is low. Jun 5, 2023 · ATAI stock closed at $1.76 and is up $0.10 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard trading hours. ATAI has a strong overall score of 70 meaning the stock holds a better value than 70% of stocks at its current price. See Atai Life Sciences N.V. (ATAI) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.ATAI Life Sciences NV Follow Share $1.11 Nov 22, 2:08:38 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Cybin Inc $0.46 CYBN2.61% Compass Pathways PLC $6.00 CMPS2.92% Mind Medicine...

According to the issued ratings of 1 analysts in the last year, the consensus rating for Arcadia Biosciences stock is Buy based on the current 1 buy rating for RKDA. The average twelve-month price prediction for Arcadia Biosciences is $15.00 with a high price target of $20.00 and a low price target of $10.00. Learn more on RKDA's analyst rating ...From July 11 to July 13, Wood purchased 947,340 shares of BFLY stock. 5. ATAI Life Sciences (ATAI) ... Stocks to Buy AMZN Stock Forecast: Predicting Amazon’s Performance in 2023 and Beyond ….

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Atai stock forecast. Possible cause: Not clear atai stock forecast.

About the ATAI Life Sciences N.V. stock forecast. As of 2023 November 11, Saturday current price of ATAI stock is 1.160$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. ATAI Life Sciences N.V. stock price has been showing a declining tendency so we believe that similar market segments …ATAI SHARE Price - ATAI Life Sciences N.V. Common Shares NASDAQ USA Technical Analysis, Forecast, Important Levels, Latest News, Interactive Charts.In today’s fast-paced business environment, accurate forecasting is crucial for making informed decisions and staying ahead of the competition. One powerful tool that can help you achieve this is a forecasting Excel template.

In the world of business, cash flow is king. Having a clear understanding of your company’s cash flow is essential for making informed financial decisions and ensuring the long-term success of your business.Find real-time DNUT - Krispy Kreme Inc stock quotes, company profile, news and forecasts from CNN Business.Ad. LendingTree. As we look ahead to 2024, some of the most promising AI-powered stock-picking platforms use natural language processing to generate actionable predictions. For example, EquBot ...

monthly dividend calendar Cybin Inc. (OTC: CLXPF) stock has returned more than 3,485% to investors in the past twelve months. The firm operates as a life sciences company concentrating on the development of psychedelic drugs. wix.com ltdbanking stocks today Atai Life Sciences (ATAI) Stock Forecast & Price Prediction. Estimation of the future price movement of Atai Life Sciences stock, based on various factors such as historical price …WebDown -34.59% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI) Zacks - Tue Jan 31, 8:35AM CST . atai Life Sciences N.V. (ATAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings... sil etf See the latest Vista Energy SAB de CV ADR stock price (VIST:XNYS), related ... ATAI Life Sciences, LianBio, or BioXcel Therapeutics? PR Newswire Oct 26, 2023 ...Since Atai Life Sciences is only going public, we don’t have any forecast for the stock. Also, being a clinical-stage company, we don’t have earnings-based metrics to value the stock. peach state healthcarefire insurance companiesgoos As of last trade ATAI Life Sciences NV (ATAI:NMQ) traded at 1.10, 4.76% above its 52-week low of 1.05, set on Oct 27, 2023. Data delayed at least 15 minutes, as of Nov 30 2023 18:35 GMT. Latest ATAI Life Sciences NV (ATAI:NMQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and …ATAI Life Sciences NV Stock Forecast. Is ATAI Life Sciences NV Stock Undervalued? The current ATAI Life Sciences NV [ ATAI] share price is $1.06. The Score for ATAI is 20, which is 60% below its historic median score of 50, and infers higher risk than normal. ATAI is currently trading in the 10-20% percentile range relative to its historical ... metropolitan west total return bond Oct 2, 2023 · 3:24 pm. Articles. atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) August 10, 2023 Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients…. August 10, 2023. first allied securitiesincome realtyidv etf Atai Life Sciences is forecasted to grow earnings and revenue by 20.7% and 73.6% per annum respectively. EPS is expected to grow by 29.2%. Return on equity is forecast to be -69.3% in 3 years.